BRPI0413791A - composto, método para o tratamento de um indivìduo humano ou animal que sofre de, ou que é suscetìvel a um distúrbio auto-imune ou uma condição inflamatória, uso de um composto, composição farmacêutica, e, processo para a prearação de compostos - Google Patents

composto, método para o tratamento de um indivìduo humano ou animal que sofre de, ou que é suscetìvel a um distúrbio auto-imune ou uma condição inflamatória, uso de um composto, composição farmacêutica, e, processo para a prearação de compostos

Info

Publication number
BRPI0413791A
BRPI0413791A BRPI0413791-4A BRPI0413791A BRPI0413791A BR PI0413791 A BRPI0413791 A BR PI0413791A BR PI0413791 A BRPI0413791 A BR PI0413791A BR PI0413791 A BRPI0413791 A BR PI0413791A
Authority
BR
Brazil
Prior art keywords
alkyl
alkylaryl
compound
cor
optionally substituted
Prior art date
Application number
BRPI0413791-4A
Other languages
English (en)
Inventor
Simon Gaines
Ian Peter Holmes
Stephen Lewis Martin
Stephen Paul Watson
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of BRPI0413791A publication Critical patent/BRPI0413791A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Soft Magnetic Materials (AREA)
  • Indole Compounds (AREA)
  • Macromonomer-Based Addition Polymer (AREA)
  • Anti-Oxidant Or Stabilizer Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Lubricants (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

"COMPOSTO, MéTODO PARA O TRATAMENTO DE UM INDIVìDUO HUMANO OU ANIMAL QUE SOFRE DE, OU QUE é SUSCETìVEL A UM DISTúRBIO AUTO-IMUNE OU UMA CONDIçãO INFLAMATóRIA, USO DE UM COMPOSTO, COMPOSIçãO FARMACêUTICA, E, PROCESSO PARA A PREPARAçãO DE COMPOSTOS". Descreve-se compostos de fórmula (I): sendo que: A representa uma ligação, C~ 1-6~alquila ou CH=CHC~ 1-4~alquila; B representa ligação, O, S, SO, SO~ 2~, CO, CR¬ 7¬R¬ 8¬, CO¬ 2¬R¬ 14¬, CONR¬ 14¬R¬ 15¬, N(COR¬ 14¬)(COR¬ 15¬), N(SO¬ 2¬R¬ 14¬)(COR¬ 15¬) ou NR¬ 14¬R¬ 15¬; D representa ligação, ou C~ 1-6~ alquila; E representa arila substituído ou heteroarila substituído ou não substituído; Q representa um anel heteroarila ou arila com 5 ou 6 membros opcionalmente substituído; X representa O, S, SO, SO~ 2~, CO, CNRS, CNOR¬ 5¬, CNNR¬ 5¬R¬ 6¬, NR¬ 11¬ ou CR¬ 7¬R¬ 8¬; Y representa CR¬ 5¬OR¬ 11¬, CR¬ 5¬SR¬ 11¬, NOR¬ 5¬, CR¬ 5¬NR¬ 6¬R¬ 11¬, SO, SO~ 2~, CO, CNR¬ 5¬, CNOR¬ 5¬ ou CS; R¬ 1¬ e R¬ 1¬<39>, sendo que cada um representa independentemente H, C~ 1-6~alquila ou C~ 1-4~alquilarila; R¬ 2¬; representa CO~ 2~R¬ 12¬, CH~ 2~OR¬ 12¬ ou CONR¬ 12¬R¬ 13¬, CONR¬ 12¬OR¬ 13¬, NR¬ 12¬COR¬ 13¬, SR¬ 12¬, PO(OH)~ 2~, PONHR¬ 12¬ ou SONHR¬ 12¬; R¬ 3¬ representa H, C~ 1-6~alquila ou C~ 1-4~alquilarila; R¬ 4¬ representa heteroarila ou arila opcionalmente substituído; Z representa uma ligação. CH~ 2~, O, S, SO, SO~ 2~, NR¬ 5¬, OCR¬ 5¬R¬ 6¬, CR¬ 9¬R¬ 10¬O ou Z, R¬ 4¬ e Q em conjunto, formam um grupo tricíclico fundido opcionalmente substituído; R¬ 5¬ e R¬ 6¬ representam, cada um, independentemente, H, C~ 1-6~ alquila ou C~ 1-4~ alquilarila; R¬ 7¬ e R¬ 8¬, sendo que cada um representa independentemente H, halo, C~ 1-6~ alquila ou C~ 1-4~ alquilarila; R¬ 9¬ e R¬ 10¬ representam, cada um, independentemente, H, C~ 1-6~ alquila opcionalmente substituído por halo, ciano, OR¬ 11¬ ou NR¬ 6¬R¬ 11¬, C~ 1-4~ alquilarila opcionalmente substituído por halo, ciano, OR¬ 11¬ ou NR¬ 6¬R¬ 11¬, OR¬ 11¬ ou, em conjunto com o N a que estão ligados, R¬ 9¬ e R¬ 10¬ formam um grupo heterocíclico: R¬ 11¬ representa H, C~ 1-6~ alquila, C~ 1-4~ alquilarila ou COR¬ 5¬; R¬ 12¬ e R¬ 13¬, cada um, independentemente, representam H, C~ 1-3~ alquila, C~ 1-3~ alquilarila ou C~ 1-3~ alquil-heteroarila ou, em conjunto com a funcionalidade a que estão ligados, R¬ 12¬ e R¬ 13¬ formam um grupo heterocíclico: R¬ 14¬ e R¬ 15¬, cada um, independentemente, representa H, C~ 1-6~ alquila, C~ 1-4~ alquilarila ou C~ 1-4~ alquil-heteroarila ou, em conjunto com a funcionalidade a que estão ligados, R¬ 14¬ e R¬ 15¬ formam um heterocíclico ou grupo heterocíclico fundido: e derivados fisiologicamente funcionais dos mesmos, processos para sua preparação, formulações farmacêuticas contendo os mesmos, e seu uso como inibidores de enzimas de metaloproteinase de matriz (MMPs).
BRPI0413791-4A 2003-09-13 2004-09-10 composto, método para o tratamento de um indivìduo humano ou animal que sofre de, ou que é suscetìvel a um distúrbio auto-imune ou uma condição inflamatória, uso de um composto, composição farmacêutica, e, processo para a prearação de compostos BRPI0413791A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0321538.1A GB0321538D0 (en) 2003-09-13 2003-09-13 Therapeutically useful compounds
PCT/EP2004/010319 WO2005026120A1 (en) 2003-09-13 2004-09-10 Matrix metalloproteinase inhibitors

Publications (1)

Publication Number Publication Date
BRPI0413791A true BRPI0413791A (pt) 2006-11-07

Family

ID=29227079

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0413791-4A BRPI0413791A (pt) 2003-09-13 2004-09-10 composto, método para o tratamento de um indivìduo humano ou animal que sofre de, ou que é suscetìvel a um distúrbio auto-imune ou uma condição inflamatória, uso de um composto, composição farmacêutica, e, processo para a prearação de compostos

Country Status (28)

Country Link
US (3) US7601729B2 (pt)
EP (3) EP2295408A1 (pt)
JP (3) JP2007505081A (pt)
KR (3) KR20060120648A (pt)
CN (1) CN1849306B (pt)
AT (2) ATE502922T1 (pt)
AU (1) AU2004272280C1 (pt)
BR (1) BRPI0413791A (pt)
CA (1) CA2538315C (pt)
CY (1) CY1109400T1 (pt)
DE (2) DE602004031991D1 (pt)
DK (1) DK1663970T3 (pt)
ES (2) ES2314436T3 (pt)
GB (1) GB0321538D0 (pt)
HR (1) HRP20080668T3 (pt)
IL (1) IL173305A (pt)
IS (2) IS2622B (pt)
MA (1) MA28039A1 (pt)
MX (1) MXPA06002458A (pt)
NO (1) NO20060540L (pt)
NZ (2) NZ545211A (pt)
PL (1) PL1663970T3 (pt)
PT (1) PT1663970E (pt)
RU (2) RU2370488C2 (pt)
SG (1) SG145685A1 (pt)
SI (1) SI1663970T1 (pt)
WO (1) WO2005026120A1 (pt)
ZA (1) ZA200602070B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0321538D0 (en) * 2003-09-13 2003-10-15 Glaxo Group Ltd Therapeutically useful compounds
EA013539B1 (ru) * 2005-02-22 2010-06-30 Рэнбакси Лабораториз Лимитед Производные 5-фенилпентановой кислоты в качестве ингибиторов матричной металлопротеиназы для лечения астмы и других заболеваний
AU2013200728B2 (en) * 2006-08-22 2014-12-18 Sun Pharmaceutical Industries Limited Matrix metalloproteinase inhibitors
JO2868B1 (en) * 2006-08-22 2015-03-15 رانبكسي لابوراتوريز ليمتد Inhibitors of metabolic protein protein enzyme
ES2569660T3 (es) 2007-06-08 2016-05-12 Mannkind Corporation Inhibidores de la IRE-1alfa
FR2949463B1 (fr) * 2009-08-26 2011-09-16 Commissariat Energie Atomique Inhibiteurs de mmp
CN103119030A (zh) 2010-07-30 2013-05-22 兰贝克赛实验室有限公司 基质金属蛋白酶抑制剂
US20140148459A1 (en) 2010-09-24 2014-05-29 Ranbaxy Laboratories Limited Matrix metalloproteinase inhibitors
EP2926808A1 (en) 2012-11-28 2015-10-07 Administración General De La Communidad Autónoma De Euskadi Use of metalloprotease inhibitors for the treatment of polycystic liver diseases
SG11201806416XA (en) 2016-02-12 2018-08-30 Astellas Pharma Inc Tetrahydroisoquinoline derivatives
CN110769866B (zh) * 2017-06-13 2022-07-29 爱惜康有限责任公司 具有可控愈合的外科缝合器

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4102024A1 (de) * 1991-01-24 1992-07-30 Thomae Gmbh Dr K Biphenylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
AU2199195A (en) * 1994-04-28 1995-11-29 Uniroyal Chemical Company, Inc. Fungicidal azole derivatives
CZ172498A3 (cs) * 1995-12-06 1998-12-16 Astra Pharmaceuticals Ltd. Sloučenina
DK0898566T3 (da) 1996-04-19 2003-03-03 Akzo Nobel Nv Substituerede benzylaminer og anvendelse deraf til behandling af depression
MY132470A (en) * 1996-05-15 2007-10-31 Bayer Corp Substituted oxobutyric acids as matrix metalloprotease inhibitors
US6242616B1 (en) * 1996-12-03 2001-06-05 The Trustees Of The University Of Pennsylvania Synthetic techniques and intermediates for polyhydroxy, dienyl lactone derivatives
US6870058B2 (en) * 1996-12-03 2005-03-22 The Trustees Of The University Of Pennsylvania Compounds which mimic the chemical and biological properties of discodermolide
US20050065353A1 (en) * 1996-12-03 2005-03-24 Smith Amos B. Synthetic techniques and intermediates for polyhydroxy dienyl lactones and mimics thereof
US5789605A (en) * 1996-12-03 1998-08-04 Trustees Of The University Of Pennsylvania Synthetic techniques and intermediates for polyhydroxy, dienyl lactones and mimics thereof
US6096904A (en) 1996-12-03 2000-08-01 The Trustees Of The University Of Pennsylvania Synthetic techniques and intermediates for polyhydroxy, dienyl lactone derivatives
US5804581A (en) * 1997-05-15 1998-09-08 Bayer Corporation Inhibition of matrix metalloproteases by substituted phenalkyl compounds
US6608052B2 (en) * 2000-02-16 2003-08-19 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as anti-inflammatory agents
JP2005504727A (ja) * 2001-04-13 2005-02-17 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 抗炎症薬として有用なウレア化合物
US7102008B2 (en) 2002-08-01 2006-09-05 Bristol-Myers Squibb Company Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme
BR0314898A (pt) * 2002-11-19 2005-08-02 Galderma Res & Dev Compostos, composição cosmética, uso cosmético de uma composição, uso de um composto e composição farmacêutica
GB0312654D0 (en) * 2003-06-03 2003-07-09 Glaxo Group Ltd Therapeutically useful compounds
GB0314488D0 (en) * 2003-06-20 2003-07-23 Glaxo Group Ltd Therapeutically useful compounds
GB0319069D0 (en) * 2003-08-14 2003-09-17 Glaxo Group Ltd Therapeutically useful compounds
GB0321538D0 (en) 2003-09-13 2003-10-15 Glaxo Group Ltd Therapeutically useful compounds
EA013539B1 (ru) * 2005-02-22 2010-06-30 Рэнбакси Лабораториз Лимитед Производные 5-фенилпентановой кислоты в качестве ингибиторов матричной металлопротеиназы для лечения астмы и других заболеваний
JO2868B1 (en) * 2006-08-22 2015-03-15 رانبكسي لابوراتوريز ليمتد Inhibitors of metabolic protein protein enzyme

Also Published As

Publication number Publication date
HK1092141A1 (en) 2007-02-02
RU2006106850A (ru) 2007-10-20
CN1849306B (zh) 2014-01-29
US8263602B2 (en) 2012-09-11
JP2011231118A (ja) 2011-11-17
EP1663970B1 (en) 2008-11-05
NO20060540L (no) 2006-04-04
RU2370488C2 (ru) 2009-10-20
EP2042488A1 (en) 2009-04-01
EP1663970A1 (en) 2006-06-07
NZ573479A (en) 2010-09-30
CA2538315A1 (en) 2005-03-24
US8343986B2 (en) 2013-01-01
IS8268A (is) 2006-01-26
US7601729B2 (en) 2009-10-13
ES2362954T3 (es) 2011-07-15
JP2012107031A (ja) 2012-06-07
WO2005026120A1 (en) 2005-03-24
IL173305A (en) 2011-01-31
RU2008146479A (ru) 2010-06-20
ATE502922T1 (de) 2011-04-15
CN1849306A (zh) 2006-10-18
SI1663970T1 (sl) 2009-04-30
AU2004272280A1 (en) 2005-03-24
DE602004031991D1 (de) 2011-05-05
ZA200602070B (en) 2007-05-30
HRP20080668T3 (hr) 2009-02-28
US20060293353A1 (en) 2006-12-28
SG145685A1 (en) 2008-09-29
PL1663970T3 (pl) 2009-04-30
MA28039A1 (fr) 2006-07-03
US20090082377A1 (en) 2009-03-26
DE602004017622D1 (de) 2008-12-18
US20100029699A1 (en) 2010-02-04
EP2295408A1 (en) 2011-03-16
CA2538315C (en) 2014-04-08
PT1663970E (pt) 2009-01-09
DK1663970T3 (da) 2009-01-12
AU2004272280B2 (en) 2011-04-21
AU2004272280C1 (en) 2011-10-27
NZ545211A (en) 2009-01-31
IS2622B (is) 2010-05-15
CY1109400T1 (el) 2014-07-02
KR20130079628A (ko) 2013-07-10
JP2007505081A (ja) 2007-03-08
ATE413384T1 (de) 2008-11-15
IS8843A (is) 2009-08-19
GB0321538D0 (en) 2003-10-15
MXPA06002458A (es) 2006-06-20
KR20120007566A (ko) 2012-01-20
EP2042488B1 (en) 2011-03-23
IL173305A0 (en) 2006-06-11
KR20060120648A (ko) 2006-11-27
ES2314436T3 (es) 2009-03-16

Similar Documents

Publication Publication Date Title
IS8843A (is) Hálfmálmaprótínasa hindra mót
BR0201697A (pt) Compostos de alfa-aminoácid0, processo para a sua preparação e composições farmacêuticas contendo os mesmos
ATE362910T1 (de) Matrix metalloprotease inhibitoren
TN2010000026A1 (fr) Nouveaux derives de 6-triazolopyridazine-sulfanyl benzothiazole et benzimidazole, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de met
BR0306150A (pt) Composto, uso de um composto, e, composição farmacêutica
AR004219A1 (es) Nuevos derivados de quinazolina, procedimientos para su preparacion, composiciones que los contienen y su uso en la preparacion de medicamentos,particularmente en el tratamiento de trastornos inflamatorios
BRPI0414514A (pt) uso de um composto, composto, e, composições farmacêuticas
EA200500342A1 (ru) Гетероциклические замещённые пиперазины для лечения шизофрении
MA27664A1 (fr) Acides gras a chaine moyenne, glycerides et analogues utilises en tant que stimulateurs de l&#39;erythropoiese
BRPI0409049A (pt) métodos de preparação de um composto, composição e composição cristalina
EA200000431A2 (ru) Новые замещенные димерные соединения, способ их получения и фармацевтические композиции, содержащие их
DE3883140D1 (de) Imidazo(2,1-b)benzothiazole und ihre saeureadditionssalze, verfahren und zwischenprodukte zu ihrer herstellung, ihre verwendung als arzneimittel und diese enthaltende pharmazeutische zubereitungen.
EA200100090A2 (ru) Новые пиперидин-4-сульфонамидные производные, способ их получения и содержащие их фармацевтические композиции
PT77231B (en) Process for the preparation of 2-nitro-1,1-ethenediamines having a hypotensive effect and their use for the preparation of pharmaceutical compositions with a hypotensive effect
MA29258B1 (fr) Nouveaux derives d&#39;oximes heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
ATE38987T1 (de) Neue 2h-1-benzopyran-2-on-derivate, verfahren zu ihrer herstellung und arzneimittel, die diese verbindungen enthalten.
IL64081A (en) N-alkoxycarbonyl-n&#39;-substituted alkyl-n&#34;-phenyl guanidines,process for their preparation and pharmaceutical compositions containing them
EA199901034A3 (ru) Новые соединения 1,2-дитиолана, способ их получения и содержащие их фармацевтические составы
EA200000530A1 (ru) НОВЫЕ 19-НОРСТЕРОИДЫ, ЗАМЕЩЕННЫЕ В ПОЛОЖЕНИИ 11β, СПОСОБ И ПРОМЕЖУТОЧНЫЕ ПРОДУКТЫ ДЛЯ ИХ ПОЛУЧЕНИЯ, ПРИМЕНЕНИЕ В КАЧЕСТВЕ ЛЕКАРСТВЕННЫХ СРЕДСТВ И СОДЕРЖАЩИЕ ИХ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ
ATE239021T1 (de) Metalloproteaseinhibitoren, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
BR0201312A (pt) Compostos de pirimidin-4-ona, processo para sua preparação e composições farmacêuticas contendo os referidos
ES2183500T3 (es) Nuevos compuestos y composiciones farmaceuticas que los contienen.
ES533657A0 (es) Un procedimiento para la preparacion de nuevos derivados de pirrolo-(2,1-a)isoquilonina.
DE59008715D1 (de) 2-Formylbenzylphosphonsäure-Derivate, deren Herstellung und ihre Verwendung zur Behandlung von durch Viren verursachte Krankheiten.
IT1213440B (it) 2-ditioalchil-diidropiridine, un metodo per la loro preparazione e composizioni farmaceutiche chele contengono.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25G Requested change of headquarter approved

Owner name: GLAXO GROUP LIMITED (GB)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2478 DE 03-07-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.